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Abstract
Background: Non-alcoholic fatty liver disease is the most common chronic liver disease in children in western
countries. Adverse early-life exposures are associated with higher liver fat percentages in children. Differential DNA
methylation may underlie these associations. We aimed to identify differential DNA methylation in newborns and
children associated with liver fat accumulation in childhood. We also examined whether DNA methylation at 22
cytosine-phosphate-guanine sites (CpGs) associated with adult non-alcoholic fatty liver disease is associated with
liver fat in children. Within a population-based prospective cohort study, we analyzed epigenome-wide DNA
methylation data of 785 newborns and 344 10-year-old children in relation to liver fat fraction at 10 years. DNA
methylation was measured using the Infinium HumanMethylation450 BeadChip (Illumina). We measured liver fat
fraction by Magnetic Resonance Imaging. Associations of single CpG DNA methylation at the two-time points with
liver fat accumulation were analyzed using robust linear regression models. We also analyzed differentially methylation
regions using the dmrff package. We looked-up associations of 22 known adult CpGs at both ages with liver fat at 10
years.
Results: The median liver fat fraction was 2.0% (95% range 1.3, 5.1). No single CpGs and no differentially methylated
regions were associated with liver fat accumulation. None of the 22 known adult CpGs were associated with liver fat in
children.
Conclusions: DNA methylation at birth and in childhood was not associated with liver fat accumulation in 10-year-old
children in this study. This may be due to modest sample sizes or DNA methylation changes being a consequence
rather than a determinant of liver fat.
Keywords: Non-alcoholic fatty liver disease, Liver steatosis, Epigenetics, Differentially methylated regions, Magnetic
resonance imaging

Background
Non-alcoholic fatty liver disease is a pathologic excess of
≥ 5% fat in hepatic cells, not caused by alcohol consumption, genetic or metabolic disorders, medication, or viral
infections [1]. Due to the high prevalence of obesity,
non-alcoholic fatty liver disease has become the most
common chronic liver disease in both children and
adults in western countries [2–5]. Non-alcoholic fatty
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liver disease is associated with an adverse cardiometabolic risk profile in children [3]. In adults, it is associated with cardio-metabolic diseases and hepatocellular
carcinoma, and it is a leading indication for liver transplantation [4, 6]. An accumulating body of evidence suggests that adverse exposures in early life contribute to
the development of obesity and non-alcoholic fatty liver
disease [5, 7].
The mechanisms underlying the observed associations
of early-life factors with liver fat in children and adults
may include changes in DNA methylation [5, 7]. DNA
methylation is an epigenetic mechanism that is highly dynamic in early life and affects the accessibility of DNA for
transcription and thereby gene expression [8]. Various
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adverse early-life factors have been associated with
differential DNA methylation [9–12]. Recent studies
using liver biopsy samples of adults with nonalcoholic fatty liver disease suggest differential DNA
methylation is cross-sectionally associated with nonalcoholic fatty liver disease [8, 13–15]. A metaanalysis of population-based cohorts in adults identified 22 cytosine-phosphate-guanine sites (CpGs) in
peripheral blood at which DNA methylation was associated with non-alcoholic fatty liver disease [6].
We hypothesized that differential DNA methylation at
birth and in childhood is associated with liver fat accumulation in children. We performed an epigenome-wide
association study (EWAS) to assess whether DNA
methylation at birth and at age 10 years is associated
with liver fat accumulation measured with magnetic resonance imaging (MRI) in 10-year-old children participating in a population-based prospective cohort study.
Analyses were focused on both single CpGs and differentially DNA methylated regions (DMRs). As a secondary analysis, we examined if DNA methylation at birth
and at age 10 years is associated with higher (> 2%) versus lower (≤ 2%) liver fat accumulation. We also examined whether DNA methylation at the 22 CpGs known
to be associated with non-alcoholic fatty liver disease in
adults, is also associated with liver fat in children [6].
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Results
Subject characteristics

The median liver fat fraction was 2.0% for both groups
(newborns 95% range 1.3, 4.6, 10-year-old children 95%
range 1.3, 5.1)). The prevalence of non-alcoholic fatty
liver disease at age 10 years was 2.2% (n = 17/785) in the
group with DNA methylation data at birth and 2.6% (n
= 9/344) in the group with DNA methylation data at age
10 years. The baseline characteristics of the study population are presented in Table 1. Non-response analyses
comparing singleton children with DNA methylation
data, with and without information on liver fat fraction
available, showed that participants in the newborn group
were slightly more often female and more often overweight, had somewhat older and higher educated
mothers, who more often stopped smoking during pregnancy compared to non-participants in the newborn
group. In the childhood group, non-response analyses
showed that participants were slightly older compared to
non-participants (Table 2).
Epigenome-wide association study of childhood liver fat
accumulation

We assessed associations of DNA methylation in cord
blood and in whole peripheral blood at 10 years with
liver fat as a continuous measure in 10-year-old children.

Table 1 Subject characteristics
Newborns

Childhood

(n = 785)

(n = 344)

Maternal characteristics
Age, mean (SD), years

32.1 ± 4.0

32.1 ± 4.0

Prepregnancy body mass index, mean (SD), kg/m2

23.2 ± 3.9

23.4 ± 4.0

Parity, n (%), nulliparous

477 (60.8%)

205 (59.6%)

Education, n (%), higher education

535 (68.2%)

232 (67.4%)

Smoking during pregnancy, n (%), continued

94 (12.0%)

43 (12.5%)

Gestational age at birth, median (95%), weeks

40.4 (37.0–42.3)

40.3 (36.9–42.4)

Age, mean (SD), years

0

9.8 ± 0.3

Males, n (%)

378 (48.2%)

170 (49.4%)

Birth weight, mean (SD), g

3556 ± 505

3578 ± 515

17.0 ± 2.1

17.1 ± 2.0

Child characteristics

2

Body mass index at 10 years, mean (SD), kg/m
Children with
Underweight, n (%)

62 (7.9)

19 (5.5)

Normal weight, n (%)

637 (81.1)

287 (83.4)

Overweight, n (%)

79 (10.1)

37 (10.8)

Obesity, n (%)

7 (0.9)

1 (0.3)

Liver fat fraction, median (95% range), %

2.0 (1.3–4.6)

2.0 (1.3–5.1)

Prevalence non-alcoholic fatty liver disease, n (%)

17 (2.2%)

9 (2.6%)

Values are observed data and represent means ± SD, medians (95% range), or numbers of subjects (valid %)
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Table 2 Comparison of child characteristics between children included and not included in the analyses
Newborns participants Non-participants
(n = 785)

P value Children
participants

(n = 604)

(n = 344)

Nonparticipants

P value

(n = 120)

Maternal characteristics
Age, mean (SD), years

32.1 ± 4.0

31.3 ± 4.5

<0.01

32.1 ± 4.0

32.5 ± 4.1

0.41

Prepregnancy body mass index, mean (SD), kg/m2 23.2 ± 3.9

23.2 ± 3.8

0.95

23.4 ± 4.0

22.7 ± 3.2

0.12

Parity, n (%), nulliparous

477 (60.8%)

365 (60.6%)

0.96

205 (59.6%)

73 (61.3%)

0.74

Education, n (%), higher education

535 (68.2%)

357 (61.1%)

<0.01

232 (67.4%)

75 (65.2%)

0.86

Smoking during pregnancy, n (%), continued

94 (12.0%)

88 (18.0%)

<0.01

43 (12.5%)

8 (9.3%)

0.70

Child characteristics
Gestational age at birth, median (95%), weeks

40.4 (37.0–42.3)

40.3 (36.3 – 42.4) 0.45

40.3 (36.9 – 42.4) 40.4 (37.6–42.4) 0.63

Age, mean (SD), years

NA

NA

NA

9.8 ± 0.3

9.7 ± 0.3

Males, n (%)

378 (48.2%)

325 (53.8%)

0.04

170 (49.4%)

61 (50.8%)

0.79

Birth weight, mean (SD), g

3556 ± 505

3528 ± 518

0.31

3578 ± 515

3547 ± 498

0.57

Body mass index, mean (SD), kg/m2

17.0 ± 2.1

17.0 ± 2.1

0.77

17.1 ± 2.0

17.2 ± 2.2

0.62

Underweight, n (%)

62 (7.9)

30 (8.1)

0.12

19 (5.5)

8 (6.7)

0.21

Normal weight, n (%)

637 (81.1)

299 (80.6)

0.05

287 (83.4)

97 (80.8)

0.42

<0.01

Children with

Overweight, n (%)

79 (10.1)

38 (6.3)

0.01

37 (10.8)

13 (10.8)

0.52

Obesity, n (%)

7 (0.9)

4 (0.7)

0.09

1 (0.3)

2 (1.7)

0.11

Values are observed data and represent means ± SD, medians (95% range), or numbers of subjects (valid %). Differences were tested using Student’s t tests and
Mann-Whitney tests for normally and non-normally distributed variables, respectively and using χ2-test for dichotomous variables

In the main models, adjusted for maternal age, education
level, early-pregnancy BMI and smoking, gestational age
at birth (cord blood analyses) or child age (childhood
analyses), child sex, cell-type proportions, and batch, we
did not observe any CpGs at birth or at 10 years to be
associated with liver fat accumulation at 10 years after
Bonferroni (p value < 1.0 × 10−7) or false-discovery rate
(FDR) correction. The Manhattan plots of both EWAS
analysis of liver fat accumulation are presented in
Additional file 1: Figure S1a and Figure S1b. Additional
file 2: Table S1 and Table S2 show the CpGs with p
values < 1.0 × 10−4 for newborns and for 10-year-old
children, respectively. We did not identify significantly
associated differentially methylated regions associated
with liver fat accumulation, nor did we find associations
of individual CpG sites with higher versus lower liver fat
accumulation. Additional file 3: Table S3 and Table S4
show the differentially methylated regions with p values
< 1.0 × 10−4 for newborns and 10-year-old children, respectively. Additional file 4: Table S5 and Table S6 show
the CpGs with p values < 1.0 × 10−4 for newborns and
for 10-year-old children for higher versus lower liver fat,
respectively. Results of the basic model and of the model
additionally adjusted for childhood body mass index
(BMI) were not substantially different from the results in
the main model. The mean percent differences in effect

estimates between the main model and the basic model,
and between the main model and the childhood BMI
model in cord blood were 2.5% and 10.9%, respectively.
In the child peripheral blood analyses at 10 years, the
mean percent differences were 1.6% and 3.9%, respectively. In Additional file 5: Table S7 and Table S8, we
show the results of the basic and childhood BMI models
for the CpGs probes with p values < 1.0 × 10−4 identified
in the main model.
Look-up of CpGs associated with adult liver fat

None of the 22 CpGs differentially methylated regions
known for their associations with non-alcoholic fatty
liver disease in adults were associated with liver fat in
children (Bonferroni corrected p value cutoff < 0.05/22 =
2.3 × 10−3, Table 3). We found no evidence for enrichment of the 22 CpGs among the 18,848 nominally significant CpGs from the cord blood analysis and among
the 23,173 nominally significant CpGs from the 10-yearold analysis (Fisher combined probability p value = 1.00
in newborns and p value = 0.68 in 10-year-old children).
Candidate genes analysis associated with liver fat

We examined if there was an enrichment of CpGs located in regions within a 4 Mb window (± 2 Mb) surrounding the 9 single-nucleotide polymorphisms (SNPs)
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Table 3 Associations of 22 adult non-alcoholic fatty liver disease-associated CpGs with liver fat fraction in children
Newborns

Children

CpG

Chromosome

Position

Gene

Effect*

SE*

P value

Effect*

SE*

P value

cg09469355

1

2161886

SKI

0.002

0.03

0.96

− 0.002

0.07

0.98

cg17901584

1

55353706

DHCR24

− 0.005

0.02

0.74

− 0.069

0.04

0.08

cg03725309

1

109757585

SARS

− 0.012

0.02

0.45

0.027

0.05

0.56

cg14476101

1

120255992

PHGDH

− 0.003

0.02

0.99

0.011

0.04

0.78

cg19693031

1

145441552

TXNIP

− 0.011

0.03

0.72

− 0.031

0.04

0.45

cg06690548

4

139162808

SLC7A11

− 0.086

0.05

0.08

− 0.027

0.06

0.67

cg05119988

4

166251189

SC4MOL

0.003

0.02

0.88

0.003

0.03

0.92

cg03957124

6

37016869

COX6A1P2

0.011

0.02

0.59

0.027

0.05

0.58

cg18120259

6

43894639

LOC100132354**

0.024

0.02

0.31

− 0.124

0.05

0.02

**

cg17501210

6

166970252

RPS6KA2

0.086

0.07

0.21

− 0.137

0.08

0.10

cg21429551

7

30635762

GARS

0.015

0.02

0.42

0.017

0.03

0.52

cg11376147

11

57261198

SLC43A1

− 0.004

0.03

0.89

0.107

0.07

0.11

cg00574958

11

68607622

CPT1A

0.028

0.04

0.43

− 0.019

0.08

0.79

cg26894079

11

122954435

ASAM

0.004

0.03

0.88

− 0.020

0.04

0.63

cg11024682

17

17730094

SREBF1

− 0.023

0.04

0.54

− 0.005

0.07

0.93

cg14020176

17

72764985

SLC9A3R1

0.006

0.03

0.84

− 0.007

0.06

0.90

cg19016694

17

80821826

TBCD

0.016

0.03

0.55

− 0.062

0.06

0.30

cg15860624

19

3811194

ZFR2

0.011

0.02

0.61

0.002

0.05

0.97

cg02711608

19

47287964

SLC1A5

− 0.025

0.03

0.44

0.004

0.06

0.95

cg08309687

21

35320596

LINC00649**

− 0.004

0.03

0.88

− 0.008

0.04

0.84

cg27243685

21

43642366

ABCG1

0.042

0.04

0.32

− 0.023

0.09

0.81

cg06500161

21

43656587

ABCG1

0.018

0.03

0.57

0.023

0.05

0.66

*

Effect estimates represent the change in liver fat fraction (%) per 10% difference in DNA methylation beta and standard error. Associations are adjusted for
maternal age, education level, early-pregnancy BMI and smoking, age at birth or child age at measurement, child sex, cell type proportions, and batch. *Gene
names added using information from the UCSC Genome Browser build hg19. Other gene names from original paper by Ma et al. 2019. BMI body mass index,
n number, SE standard error

identified to be associated with non-alcoholic fatty liver
disease in adults, among all nominally significant CpGs
in our analyses [16, 17]. A total of 7225 CpGs were
present in these regions in the newborn dataset and
7244 CpGs in the 10-year-old dataset. In newborns, 299
of these CpGs were nominally significant (p value <
0.05). In 10-year-old children, this was the case for 347
CpGs. There was no enrichment for CpGs associated
with liver fat accumulation at either age (Fisher combined probability p value = 0.47 in newborns and p value
= 0.86 in 10-year-old children).
Top CpG probes functions and related biological processes

In an explorative analysis, significantly enriched gene
ontology (GO) terms based on the annotated genes of
the 32 CpG probes with p values < 1.0 × 10−4 in cord
blood pointed towards processes related to triglyceride,
acylglycerol and lipid metabolic processes, digestive tract
development, digestive system development, and digestive tract morphogenesis, among others (Additional file 6:
Table S9). The same analysis using the 76 CpG probes

with p values < 1.0 × 10−4 in child peripheral blood revealed processes related to cell cycle functions, organ morphogenesis, and development, among others (Additional
file 6: Table S10). We did not observe the functional enrichment of Kyoto Encyclopedia of Genes and Genomes
(KEGG) terms ((FDR < 0.05). Next to this, we did not observe significant enrichment of DNAse hypersensitivity
sites among the CpG probes with p values < 1.0 × 10−4
(smallest p value in cord blood analyses 0.09 and in childhood analyses 0.25).

Discussion
In the first epigenome-wide association study on liver fat
accumulation in children, we did not observe differential
DNA methylation in newborns or 10-year-old children
related to liver fat accumulation analyzed as a continuous measure or related to higher versus lower liver fat
accumulation measured by MRI at age 10 years. Also,
DNA methylation at 22 CpGs known to be associated
with non-alcoholic fatty liver disease in adults was not
associated with liver fat in children.
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Interpretation of main findings

Non-alcoholic fatty liver disease has an increasing prevalence in both children and adults [5, 18]. It is a major risk
factor for adverse cardio-metabolic health in children and
for cardio-metabolic diseases and liver diseases in adults
[3, 4, 6]. Adverse early-life factors have been described to
be associated with liver fat development [5, 7]. These associations may be explained by DNA methylation changes
in response to these early-life exposures that lead to liver
fat development [5, 19].
Among adults, it has been demonstrated that differential
DNA methylation is present in liver biopsy samples of
adults with non-alcoholic fatty liver disease [8, 13–15, 20].
All these studies used liver histology, the current gold
standard for diagnosing non-alcoholic fatty liver disease
[2, 5]. As a consequence, these studies are limited by small
sample sizes, histologically heterogeneous groups varying
in the severity of the non-alcoholic fatty liver disease,
older study populations, wide BMI ranges, and having
only few or no healthy controls. None of these reports
controlled for cell heterogeneity in their analyses. A recent
meta-analysis of four multiethnic population-based cohort
studies in adults showed that DNA methylation at 22
CpGs in peripheral blood was associated with nonalcoholic fatty liver disease diagnosed with either computed tomography or ultrasound imaging (FDR < 0.05)
[6]. In this study, in newborns and 10-year-old children
we did not observe differential DNA methylation at single
CpGs or differentially methylated regions in cord blood or
child peripheral blood in association with MRI diagnosed
liver fat accumulation in 10-year-old children. The associations of the 22 CpGs identified in adults could also not
be replicated in children [6]. It is possible that small, but
potentially biologically important DNA methylation differences may be associated with liver fat accumulation in
children. These differences would be difficult to detect in
the moderate sample size of the current study. Besides
this, the variability in liver fat accumulation in this population of children was relatively small, which may also partly
explain the lack of identified associations. In addition, our
study population is a relatively lean population. Associations of DNA methylation with liver fat accumulation may
be more apparent among higher-risk populations, as observed in adult studies [8, 13–15, 20]. Another possibility
is that DNA methylation truly is not associated with liver
fat accumulation in children. As has been suggested for
phenotypes such as obesity, differential DNA methylation
may be mostly a consequence rather than a cause of liver
fat accumulation. If that is indeed the case, then the duration of exposure to increased liver fat in this population
of 10-year-old children may not have been sufficient to induce differential DNA methylation [21].
The present population-based study is the first to
examine the association of differential DNA methylation
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with liver fat fraction measured with MRI in children.
Although the hypothesis of early-life factors contributing
to the development of liver fat accumulation through
DNA methylation cannot be completely discarded based
on this study, we found no evidence to support associations of differential DNA methylation in newborns or
children with liver fat accumulation at 10 years. Future
studies should investigate in large longitudinal studies
the associations of differential DNA methylation with
liver fat accumulation in children.
Methodological considerations

The strengths of this study are the prospective and
cross-sectional analyses with information on DNA
methylation at two ages. We used a sensitive imagingbased method to enable non-invasive measurement of
liver fat [22, 23]. Although our sample size is relatively
large for epigenome-wide analyses, it might still be too
small to detect more minor effect sizes [8, 13–15]. We
identified no Bonferonni or FDR significant associations
for differential DNA methylation in cord blood and in
child peripheral blood at 10 years to be associated with
liver fat accumulation in childhood. Therefore, the pathway analyses based on the annotated genes of the CpG
probes with p values < 1.0 × 10−4 need to be carefully
interpreted. Many of the enriched pathways are based
on a relatively low number of genes. As such, the results
of the pathway analysis should be considered exploratory
and need further confirmation. To the best of our knowledge, similar data on DNA methylation and MRImeasured liver fat accumulation in children are not currently available elsewhere. DNA methylation was measured in blood, which may differ from DNA methylation
in liver cells. The relatively small number of children
with obesity in the included sample indicates a selection
towards a lean population that may affect the
generalizability of our findings.

Conclusions
DNA methylation at birth and in childhood was not associated with liver fat accumulation in 10-year-old children in this study. This may be due to modest sample
sizes or DNA methylation changes being a consequence
rather than a determinant of liver fat. Future studies
should investigate in large longitudinal studies the associations and timing of differential DNA methylation with
liver phenotypes in children.
Methods
Study design

This study was embedded in the Generation R Study, a
population-based prospective cohort from early fetal life
onwards, based in Rotterdam, the Netherlands [24]. The
study has been approved by the Medical Ethical Committee
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of the Erasmus MC, University Medical Center Rotterdam
(MEC 198.782/2001/31). Written informed consent was
obtained for all participants [24]. All 9778 participating
live-born children were born between April 2002 and January 2006. DNA methylation was measured in a randomly
selected European-ancestry subset of 1396 newborns and
464 10-year-old children. The liver fat MRI measurements
were performed in a subgroup of children at age 10 years.
We excluded children without complete data on liver fat
fraction and covariates. The population for analysis of this
study comprised 785 newborns and 344 10-year-old children (Fig. 1).
DNA methylation

DNA was extracted from cord blood and whole peripheral
blood at 10 years using the salting-out method. Five hundred nanograms of DNA per sample underwent bisulfite
conversion using the EZ-96 DNA Methylation kit (Shallow) (Zymo Research Corporation, Irvine, CA, USA).
Samples were plated randomly onto 96-well plates. Samples were processed with the Illumina Infinium HumanMethylation450 (450k) BeadChip (Illumina Inc., San
Diego, CA, USA). Quality control of analyzed samples was
performed using standardized criteria. Quality control and

Fig. 1 Study participants flow chart
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normalization of the HumanMethylation450 BeadChip
array data was performed according to the Control Probe
Adjustment and reduction of global CORrelation (CPACOR) workflow using R [25, 26]. Probes that had a detection p value ≥ 1E− 16 were set to missing per array. Next,
the intensity values were quantile normalized for each of
the six probe-type categories separately: type II red/green,
type I methylated red/green, and type I unmethylated red/
green. Beta values were calculated as the proportion of
methylated intensity value to the sum of methylated and
unmethylated intensities plus 100. Arrays with observed
technical problems such as failed bisulfite conversion,
hybridization or extension, as well as arrays with a sex
mismatch were removed from subsequent analyses.
Additionally, only arrays with a call rate > 95% per
sample were processed further. Probes on the X and
Y chromosomes were excluded from the analyses.
The final datasets contained 457,774 probes in the
newborn dataset and 458,563 probes in the 10-yearold dataset. For all CpGs and differentially methylated
regions, the official gene name of the nearest gene
was noted using Illumina’s annotation information
and we enhanced the annotation provided by Illumina
with the UCSC Genome Browser build hg19 [27, 28].
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Liver fat fraction at 10 years

We measured liver fat using a 3.0 Tesla MRI (Discovery
MR750w, GE Healthcare, Milwaukee, WI, USA) [1, 22–24].
The children wore light clothing without metal objects
while undergoing the body scan. A liver fat scan was performed using a single-breath-hold, 3D volume and a special
3-point proton density-weighted Dixon technique (IDEAL
IQ) for generating a precise liver fat fraction image [29].
The IDEAL IQ scan is based on a carefully tuned 6-echo
echo-planar imaging acquisition. The obtained fat-fraction
maps were subsequently analyzed by the Precision Image
Analysis (PIA, Kirkland, WA, USA) using the sliceOmatic
(TomoVision, Magog, QC, CAN) software package. All extraneous structures and any image artifacts were removed
manually [30]. The liver fat fraction was measured independent of any outcome, determined by taking four samples of at least 4 cm2 from the central portion of the
hepatic volume. Subsequently, the mean signal intensities
were averaged to generate an overall mean liver fat fraction
estimation. Liver fat fraction measured with IDEAL IQ
using MRI is reproducible, highly precise, and validated in
adults [31, 32]. As previously described, non-alcoholic fatty
liver disease was defined as liver fat fraction ≥ 5.0%
[1, 32, 33]. We studied liver fat accumulation across
the full spectrum as our primary objective. As the
secondary objective, we dichotomized liver fat into
low, ≤ 2.0%, and high, > 2.0%, liver fat accumulation.
This cutoff was based on the median in our population and on previous work from our group describing
that liver fat accumulation above 2.0% is already associated with an increased cardio-metabolic risk profile
in children [34]. Due to the lower numbers of cases,
we could not dichotomize liver fat accumulation
based on the clinical cutoff of ≥ 5.0%.
Covariates

At enrolment in the study, information on maternal age
and educational level was obtained by questionnaires.
Maternal smoking during pregnancy was assessed by
questionnaires in pregnancy. We measured maternal
height and weight at enrolment to calculate earlypregnancy BMI [35]. Information on gestational age at
birth, child sex, and age at 10 years visit was obtained
from medical records. We measured height and weight
in the children, without shoes and heavy clothing. Childhood BMI was calculated and sex- and age-adjusted
childhood BMI standard deviation scores were calculated (Growth Analyzer 4.0, Dutch Growth Research
Foundation) [36].
Look-up study of adult CpGs associated with liver fat

We examined in our data the associations of the 22
CpGs known from previous literature to be associated
with liver fat accumulation in adults with liver fat
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accumulation in children [6]. A Bonferroni corrected p
value < 0.05/22 = 2.3 × 10−3 was used to define significance. We also evaluated whether the 22 CpGs were
enriched among CpGs with a p < 0.05 in our results
using a hypergeometric test.
Genes previously associated with liver fat

We assessed the number of nominally significant single CpGs from our analyses that were located within
a 4 Mb window (± 2 Mb) surrounding the 9 SNPs
identified in 2 previous genome-wide association
studies (GWAS) of liver fat accumulation in adolescents and adults of European descent [16, 17]. With
a hypergeometric test, we calculated enrichment of
the CpGs surrounding the 9 SNPs among CpGs with
a p < 0.05 in our results.
Pathway analysis

To identify biological processes associated with the genes
annotated to the CpG probes with p values < 1.0 × 10−4
identified in cord blood and in child peripheral blood at
10 years associated with liver fat accumulation, we used
the DAVID version 6.8 released October 2016 bioinformatics resource to test for enrichment in GO biological
processes and KEGG pathways [37]. The online program
epigenetic Functional element Overlap analysis of the Results of Genome-Wide Association Study Experiments
(eFORGE) was used to examine enrichment for DNAse
hypersensitivity site enrichment among the most significantly associated CpGs in both cord blood and in child
peripheral blood at 10 years [38].
Statistical analysis

First, non-response analysis was conducted among
singleton children with DNA methylation data, and with
or without complete data on liver fat and covariates
available, using Student’s t tests, Mann-Whitney tests,
and chi-square tests. Second, we used robust linear regression models to assess the associations of DNA
methylation in cord blood and in whole peripheral blood
at 10 years with liver fat fraction as a continuous measure in 10-year-old children [26]. The analyses were performed in three models, namely, a basic model (adjusted
for gestational age at birth, child sex, cell type proportions, and batch), a main model (additionally adjusted
for maternal age, education level, early-pregnancy BMI,
and smoking), and a childhood BMI model (additionally
adjusted for childhood BMI at 10 years). The statistical
models for DNA methylation measured in 10-year-old
children were the same, with the only difference that
they were adjusted for child age at the time of measurement instead of gestational age at birth. We adjusted for
leukocyte subtypes using the cord blood-specific Gervin
reference for the cord blood analyses and the Reinius
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reference set for the analyses at 10 years using the minfi
Bioconductor package in R [39–42]. Included covariates
were based on previous studies and strong correlations
with DNA methylation and liver fat [2, 6]. Since the outcome of liver fat had a skewed distribution, it was natural log-transformed. Multiple testing was accounted for
using Bonferroni correction, with CpGs with a p value <
1.0 × 10−7 considered significant. Additionally, we
planned to report results using FDR correction for multiple testing, using the method by Benjamini and Hochberg [43]. Third, we identified differentially methylated
regions using the dmrff package (https://github.com/per
ishky/dmrff), which identifies differentially methylated
regions by combining EWAS summary statistics from
nearby CpGs [44]. Significant differentially methylated
regions were defined based on the following criteria:
(1) within one differentially methylated region, the
distance between two neighboring probes can be at
most 500 base pairs; (2) the regions have nominal
EWAS p values < 0.05, and (3) EWAS effect estimates
for the individual CpGs in a differentially methylated
regions have the same direction. All analyses were
performed using R version 3.4.3 [26]. All authors had
access to the study data and reviewed and approved
the final manuscript.
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